Even when switched to a 2-month intravitreal injection regimen of aflibercept, patients with resolved diabetic macular edema continued to experience capillary perfusion density loss and increased foveal avascular zone areas through 24 months, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.
“Although capillary perfusion density is a relatively new biomarker for monitoring diabetic retinopathy, and further studies defining clinical correlations are needed, the findings from this study support initiating anti-VEGF therapy earlier in
Uncategorized